Bregal Milestone Announces the Sale of Epassi to TA Associates and Warburg Pincus
9.8.2023 15:00:00 EEST | Business Wire | Press release
Bregal Milestone, a leading pan-European technology growth private equity firm, today announced the sale of Epassi Group (“Epassi”), a market leader in the provision of employee benefits within the Nordics, and a leading player in the UK, Ireland, and Italy, to TA Associates and Warburg Pincus LLC.
Founded in 2007 and based in Espoo, Finland, Epassi is a leading provider of mobile payment solutions for the provision of employee benefits and other services. With over 13 million users, Epassi's mobile payment solution allows employees to easily access their employee benefits, such as meal vouchers, gym memberships, and parking passes, with a single app. In addition, the Epassi app can be used to pay for goods and services at over 59,000 service providers. As one of the fastest growing Nordic companies, Epassi was named to the Financial Times’ 1000 Fastest Growing Companies in Europe in 2019, 2022 and 2023.
Since Bregal Milestone’s initial investment in 2019, Epassi has cemented its leadership position and undergone a period of accelerated growth, including:
- Increasing revenue (GMV) 9x
- Increasing net revenues 6x
- Increasing EBITDA 7x
- Completing five add-on acquisitions across Europe
- Expanding its global footprint into Sweden, the UK, Ireland, and Italy
- Recruiting key C-level leadership including CEO Pekka Rantala and CFO Regina Duzanskaj
- Optimizing sales and profitability via our in-house data analytics capabilities delivered by Bregal Milestone’s in-house value creation team, Milestone Performance Partners
- Executing ESG-positive actions which resulted in a 38% improvement in Scope 1 & 2 emissions, and an independent rating as “best practice” against KPIs for 4 key ESG focus areas - Board Oversight, Cybersecurity and Privacy policies, Social Impact actions, and Business Integrity policies and results
“Bregal Milestone has been instrumental to our growth over the past several years and we believe that the timing of passing the ownership torch is ideal. With Bregal Milestone’s help, we have successfully expanded beyond the Nordics, and outside of our core business in the provision of employee benefits. We believe that with the scalable technology we have in place, we are sufficiently prepared to continue to scale into additional geographies and adjacent business areas in our next stage of growth,” says Pekka Rantala, CEO of Epassi.
“It has been a tremendous privilege to work with Risto, Pekka, and the talented Epassi leadership team to help build enormous value for the company's passionate customers, employees, and shareholders. We are proud to have helped build one of Europe’s leading employee benefits disruptors, exponentially growing revenues and profitability since our initial investment in 2019. From day one this partnership had a relentless focus on teamwork, high performance, and excellence,” added Cyrus Shey, co-founder and Managing Partner at Bregal Milestone.
“During our ownership, our successful M&A activity helped to expand Epassi’s business into five European markets, cementing our position as one of the leading pan-European employee benefits payments providers,” said Saachi Oza, Principal at Bregal Milestone.
In addition to our M&A activity, we were pleased to have worked with Pekka to build a talented leadership team and provide stewardship and support across several areas including the Epassi go-to-market strategy, their technology evolution, operational integration, and ESG. We wish Epassi continued success in their next stage of growth,” added Rob Hetherington, Epassi Chairman, Partner, and Head of Milestone Performance Partners (Bregal Milestone’s in-house value creation team).
Terms of the transaction were not disclosed. The transaction is subject to customary closing conditions. J.P. Morgan acted as exclusive financial advisor and White & Case acted as legal counsel to Bregal Milestone and Epassi.
About Epassi
Epassi, founded in 2007 in Helsinki, is a market leader in the provision of employee benefits within the Nordics, Italy, and the UK. The unique and scalable solution drives mobile tech and payment solutions to open up a world of health and well-being possibilities, combining all benefits in one user-friendly service. Epassi Group is Europe’s leading digital solution for employee benefits, with a reach of nearly 13 million users, over 13,500 employers, and more than 59 000 service providers. Epassi is a trailblazer fintech company in the Nordic countries and has been awarded by the Financial Times as one of the fastest growing companies in Europe in 2022 and 2023.
Epassi – Boosting everyday well-being.
www.epassi.com
About Bregal Milestone
Bregal Milestone is a leading technology growth private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and strategic assistance to support market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with over €16 billion in assets under management. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809476156/en/
Contact information
Jillian Hazelton
Head of Marketing & Communications
Jillian.hazelton@bregal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 10:00:00 EET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
